Highlights from ADA 85th Scientific Sessions
Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, IL, USA, taking place 20-23 June 2025!
Supported by an unrestricted educational grant from Lilly and Novo Nordisk.
Part 1
Ramzi Ajjan
Over-the-Counter Continuous Glucose Monitoring – Data for All or a Disaster Waiting to Happen?
Ramzi Ajjan
If You Had to Pick Just One – GLP-1RA, GIP/GLP-1RA or SGLT2i for Type 2 Diabetes?
Roger Chen
When the Treatment of Type 2 Diabetes Becomes Nuanced
Roger Chen
Bridging the Gap – The Brain-Peripheral Nervous System Connection in Diabetes
Sof Andrikopoulos
Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists – Can They Become Players?
Sof Andrikopoulos
Diabetes and Peripheral Artery Disease – Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial
Tania Markovic
Why Are We Still Recommending Low-Fat Dairy?
Mark Cooper
Efficacy and Safety of CagriSema in Adults with Overweight/Obesity – The REDEFINE 1 and REDEFINE 2 Clinical Trials
Part 2
Thomas Kay
Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy
Christopher Nolan
New Perspectives on Fetal and Placental Responses to Diabetes and Its Treatment
Alex Viardot
Do GLP-1/GIP-RAs Worsen or Improve Mental Health and Suicidality?
Jonathan Shaw
Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide
Jonathan Shaw
Diabetes and Peripheral Artery Disease – Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial
Sarah Glastras
Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide
So-Hun Kim
Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide
Tamara Milder
Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide
Elif Ekinci
Results from REGENT-1, an Open-Label, Prospective Study in Type 2 Diabetes
Angela Lee
The Role of CGM in Staging Early Type 1 Diabetes
Sarah Glastras
Glucometabolic Outcomes in Patients with Concurrent Overweight/Obesity and Type 1 Diabetes following Prolonged GLP-1 RA Treatment – A Systematic Review and Meta-analysis
Joanna Gong
Edwin Bierman Award Lecture – Diabetes and Cardiovascular Disease – An Evolving Story with Multiple Dimensions
Jihye Heo
SOUL Rationale, Design, and Baseline Characteristics
So-Hun Kim
First Report of a Phase 3 RCT of Orforglipron, a Small Nonpeptide GLP-1RA, as Monotherapy in Drug-Naïve Type 2 Diabetes with Inadequate Glycemic Control – The ACHIEVE-1 Trial
Yong-Ho Lee
Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes – A 52-Week Phase 2 Study
Hung-Yuan Li
Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists – Can They Become Players?
Samuel Chen
5 Take-Aways from ADA 2025
Yau-Jiunn Lee
Highlights from ADA 2025
Horng-Yih Ou
Controversies in Continuous Glucose Monitoring
Yong-Ho Lee
Metabolic and Molecular Characteristics of MASH
Lee-Ling Lim
Lancet Journal Symposium – Early-Onset Type 2 Diabetes
Highlights will be available at the end of the conference. Stay tuned!
Day 4
Day 4 highlights will be available soon. Stay tuned!
TBC
You may also like
Page 2 of 2